Novocure Limited (NVCR)
| Market Cap | 20.86B |
| Revenue (ttm) | 527.23M |
| Net Income (ttm) | 11.73M |
| Shares Out | 103.41M |
| EPS (ttm) | 0.10 |
| PE Ratio | 1,862.02 |
| Forward PE | 10,000.00 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 6 |
| Last Price | $193.65 |
| Previous Close | $201.75 |
| Change ($) | -8.10 |
| Change (%) | -4.01% |
| Day's Open | 199.03 |
| Day's Range | 189.39 - 199.95 |
| Day's Volume | 828,358 |
| 52-Week Range | 55.40 - 220.48 |
Did the market overreact to the company's good news?
Novocure missed quarterly sales expectations Thursday as total U.S. patients actively using its cancer treatment declined for the first time ever — prompting NVCR stock to topple. The post Novocure Stoc...
Shares of NovoCure (NASDAQ:NVCR) fell 2.7% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 200.00% year over year to ($0.04), which missed the...
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR #earnings--Novocure reported financial results for the first quarter of 2021 and provided a company update.
NovoCure (NVCR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
NovoCure Limited (NVCR) has moved higher as of late, but there could definitely be trouble on the horizon for this company.
Stock Market Slumps On Biden Capital Gains Tax Plan; Novocure Strong, HubSpot, Marriott Set Up
Stock market slumps on Biden capital gains tax plan; Novocure strong, HubSpot, Marriott set up. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock list...
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR #lcsm--The U.S. FDA has approved the IDE application to initiate the KEYNOTE-B36 trial, a collaboration between Novocure and MSD in NSCLC.
Once a stock goes up 50% in a single day, it can be hard to keep the momentum going.
The company's Tumor Treating Fields therapy looks very promising in treating lung cancer.
Grace Capital's Catherine Faddis on finding market opportunity
Catherine Faddis, Founder and CEO of Grace Capital, joins Worldwide Exchange to discuss her market outlook.
Novocure has provided stellar returns over the last five years, now up 17 times. Recent positive news may keep its stock going up.
Over the past few months we have discussed why Novocure stock (NASDAQ: NVCR) was vulnerable to downside risk, given its large rally and a delay in clinical trials.
With the trading day about halfway over, the broad markets were again somewhat mixed.
NovoCure (NVCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t...
Novocure exec chairman on studying Tumor Treating Fields
Novocure Executive Chairman Bill Doyle discussed studying Tumor Treating Fields, electric fields that disrupt cancer cell division, in stage 4 non-small cell lung cancer.
The oncology specialist's investigational cancer treatment could be a game-changer.
Novocure Ltd (NASDAQ: NVCR) shares are trading higher after a data monitoring committee said the interim analysis of the company's Phase 3 LUNAR trial would be accelerated. NovoCure develops commercial-...
A trial examining the use of Novocure's tumor-treating field technology in non-small cell lung cancer patients could enroll fewer patients over a shorter period, based on recommendations by an independe...
NVCR stock is skyrocketing on Tuesday after cancer treatment firm Novocure received great news regarding its phase 3 tumor treatment trial. The post NVCR Stock: The Cancer Therapy News That Has Novocure...
An independent board gave Novocure the go-ahead on Tuesday to recruit fewer patients for a study in lung-cancer treatment. The news sent NVCR stock rocketing.
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR #lcsm--Novocure announced an update on its phase 3 pivotal LUNAR trial of TTFields in stage 4 non-small cell lung cancer following platinum failure.
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced 26 presentations on Tumor Treating Fields suggesting broad applicability of Tumor Treating Fields at the AACR Annual Meeting 2021.
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure announced today that it will report financial results for the first quarter 2021 on April 29, 2021, before the U.S. financial markets open.
According to the Trefis Machine Learning Engine, which identifies trends in a company's stock price using over 15 years of historical stock data, returns for NVCR stock average around 5% in the next one...
In late December, we highlighted that the rally in Novocure stock appeared to be overdone. Yesterday, there were multiple developments around the company, including its Q4 results.
The company announced delays of several clinical studies, with one analyst also predicting slower growth ahead.
Novocure on Thursday reported adjusted earnings of 5 cents per share on $143.95 million in sales for its fourth quarter. In response, NVCR stock skidded.
NovoCure (NVCR) delivered earnings and revenue surprises of -69.23% and -0.01%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR #earnings--Novocure today reported financial results for the quarter and full year ended December 31, 2020, and provided a company update.
NovoCure (NVCR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
NovoCure (NVCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Timothy J. Scannell, President and Chief Operating Officer of Stryker Corporation, has been elected to Novocure's board of directors.
A new paradigm in cancer treatment is developing
Shares of Novocure continue to trounce the overall markets return. The performance is justified as the company remains in the early innings of its growth ascendancy.
Investors need to pay close attention to NovoCure (NVCR) stock based on the movements in the options market lately.
ST. HELIER, Jersey--(BUSINESS WIRE)---- $NVCR--Novocure reported operating statistics and preliminary, unaudited net revenues and cash balances for the fourth quarter and full year 2020.
After a stellar 3x rise since the March 23 levels of this year, at the current price of around $170 per share we believe Novocure stock, a company working on an innovative cancer treatment alternative u...
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure will participate virtually in the 39th Annual J.P. Morgan Healthcare Conference on January 11 through January 14, 2021.
Why Novocure, Leading Medical Devices Stock, Is One To Watch In 2021
Novocure is a medical devices company launched in 2000 to test a theory put forth by Yoram Palti, a professor of physiology and biophysics. Novocure that thinks of themselves as "sort of a hybrid biotec...
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced national reimbursement in Switzerland for Optune in combination with temozolomide for the treatment of newly diagnosed GBM.
ST. HELIER, Jersey--(BUSINESS WIRE)-- #btsm--Novocure announced the first patient has been enrolled in its global phase 3 TRIDENT trial.
Stock Market Analysis: Can Bulls Keep Running After A Big Week? Novocure, Intuitive Surgical Strong
Stock market analysis: Can bulls keep running after another big week? Novocure, Intuitive Surgical strong.
Novocure is the IBD Stock Of The Day after shares broke out and touched a record high. Investor enthusiasm is frothing NVCR stock with several important studies due in 2021.
Dow At New High: Google, PayPal Flash Buy Signals; Novocure Tumbles
Dow Jones hits record high: Google, PayPal flash buy signals; Novocure tumbles. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, investing dat...
The most likely culprit: profit-taking.
Rebounds from the 10-week line and breaking trend lines offer ways to start early positions in leaders. AMD, Twilio and Novocure offer both buy signals now.
Stock market analysis; Novocure Flashes Several Buy Signals, Qorvo Sets Up New Entry
Stock market analysis; Novocure flashes several buy signals, Qorvo sets up new entry. Investor's Business Daily has been helping people invest smarter results by providing exclusive stock lists, investi...
ST. HELIER, Jersey--(BUSINESS WIRE)--Novocure announced 43 presentations on Tumor Treating Fields will be featured at the Society for Neuro-Oncology 2020 Virtual Annual Meeting.
About NVCR
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma. It is also developing products for brain metastases, non-small cell lung cancer, pancreatic cancer, gastric cancer, ovarian cancer, liver cancer, and mesothelioma. The company markets its products in the European Union, Japan, and int... [Read more...]
| Industry Medical Instruments & Supplies | IPO Date Oct 2, 2015 |
| CEO Asaf Danziger | Employees 1,023 |
| Stock Exchange NASDAQ | Ticker Symbol NVCR |
Analyst Forecasts
According to 9 analysts, the average rating for Novocure stock is "Hold." The 12-month stock price forecast is 191.71, which is a decrease of -1.00% from the latest price.